IL26抗体;IL26 Antibody—艾普蒂 新品

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P13337(IL26 Antibody) at dilution 1/65. (Original magnification: ×200)    

  
  

Interleukin-26 (IL-26), a member of the IL-10 cytokine family, is primarily produced by activated T cells (particularly Th17 subsets), natural killer cells, and macrophages. Structurally distinct, it features a unique six-helix bundle fold and signals through a heterodimeric receptor complex composed of IL-20R1 and IL-10R2. Initially identified for its antimicrobial properties, IL-26 exhibits dual roles in immune regulation. It promotes inflammation by enhancing Th17 responses, stimulating epithelial cells to release pro-inflammatory cytokines (e.g., IL-1β, IL-6), and recruiting neutrophils via chemokine induction. Conversely, it directly disrupts bacterial membranes, acting as an antimicrobial peptide in mucosal barriers.

IL-26 antibodies, crucial for research and therapeutic exploration, enable detection of IL-26 expression in autoimmune and chronic inflammatory diseases. Elevated IL-26 levels correlate with pathologies like rheumatoid arthritis, psoriasis, inflammatory bowel disease, and chronic pulmonary inflammation. Neutralizing antibodies targeting IL-26 or its receptors are being investigated to mitigate pathogenic inflammation while preserving antimicrobial functions. Challenges remain in understanding tissue-specific signaling nuances and balancing therapeutic efficacy with potential immunosuppressive risks. Recent studies also explore IL-26 as a biomarker for disease severity, underscoring its evolving role in translational immunology.